COMPANY INTELLIGENCEWhat the linked records show
MedtechLedger currently links 8 FDA records to the applicant name Ventana Medical Systems, Inc.. 7 entries are PMA supplements. 1 entry is a 30-day notice. These are records held by this publication, rather than a count of the company’s entire portfolio.
The dated entries run from Jul 31, 2025 to Aug 25, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.
Product code MVC appears in 3 of the 8 linked filings. The collection spans 3 FDA product codes and 3 original PMA application families. These figures describe the filings available here; they do not establish the company’s total device sales or market share.
The largest PMA family in this collection is P190031, with 3 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes.
Applicant mailing address recorded by FDA: 1910 E. Innovation Park Dr., Tucson, AZ, 85755. Recorded on P990081/S060, decision dated Aug 25, 2026.
Device categories in this collection
System, Test, Her-2/Neu, Ihc; Chromogenic In Situ Hybridization, Nucleic Acid Amplification, Her2/Neu Gene, Breast Cancer; Immunocytochemistry assay, p16/Ki-67.
Changes described in PMA records
FDA’s recorded scope: Approval for the PATHWAY anti-HER-2/neu (4B5) Rabbit Monoclonal Primary Antibody as a companion diagnostic (CDx) for identifying patients with gastroesophageal adenocarcinoma (gastric, gastroesophageal junction, and esophageal adenocarcinoma) who may be eligible for treatment with ZIIHERA (zanidatamab).
Aug 25, 2026 · Panel TrackFDA’s recorded scope: Approval of VENTANA HER2 Dual ISH DNA Probe Cocktail to add the indication for use as a companion diagnostic (CDx) for identifying patients with gastroesophageal adenocarcinoma (GEA; gastric, gastroesophageal junction and esophageal adenocarcinoma) who many benefit from treatment with ZIIHERA (zanidatamab).
Aug 25, 2026 · Panel TrackFDA’s recorded scope: Approval to include HER2 Dual ISH DNA Probe Cocktail as a companion diagnostic indication for the determination of HER2 gene amplification status in patients with breast cancer who may benefit from treatment with ENHERTU (fam-trastuzumab deruxtecan-nxki).
May 15, 2026 · Normal 180 Day TrackFDA’s recorded scope: Approval to include the PATHWAY anti-HER-2/neu (4B5) Rabbit Monoclonal Primary Antibody (PATHWAY anti-HER2 (4B5) antibody) as a companion diagnostic indication for the detection of HER2 antigen in patients with breast cancer who may benefit from treatment with ENHERTU (fam-trastuzumab deruxtecan-nxki).
May 15, 2026 · Normal 180 Day TrackFDA’s recorded scope: This 180-day supplement is to expand labeling of the PATHWAY anti-HER-2/neu (4B5) Rabbit Monoclonal Primary Antibody assay for use as a companion diagnostic to identify patients with HER2-positive, advanced or metastatic breast cancer who may be eligible for treatment with ENHERTU (fam-trastuzumab deruxtecan-nxki) in combination with PERJETA (pertuzumab) as first-line treatment.
Dec 15, 2025 · Normal 180 Day TrackSubsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.